RILCAPTON

This brand name is authorized in Cyprus, Hong Kong, Malta

Active ingredients

The drug RILCAPTON contains one active pharmaceutical ingredient (API):

1 Captopril UNII 9G64RSX1XD - CAPTOPRIL

Captopril is a highly specific, competitive inhibitor of angiotensin-I converting enzyme (ACE inhibitors). Inhibition of ACE results in decreased plasma angiotensin-II, which leads to decreased vasopressor activity and to reduced aldosterone secretion. In patients with hypertension, captopril causes a reduction in supine and erect blood pressure, without inducing any compensatory increase in heart rate, nor water and sodium retention. Read about Captopril

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RILCAPTON Tablet	Υπουργείο Υγείας (CY)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C09AA01	Captopril	C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09A ACE inhibitors, plain → C09AA ACE inhibitors, plain
Discover more medicines within C09AA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: HK	Department of Health Drug Office	Identifier(s): 41933, 41934
Country: MT	Medicines Authority	Identifier(s): AA032/05803, AA032/05804